Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

 Relief Therapeutics Holdings S.A. is a biopharmaceutical company seeking to provide patients with many therapeutic benefits from dangerous diseases with all unmet needs. The company announced the appointment of David McCullough as Senior Director and Head of U.S. Market Access on August 22. 

In the newly created position, the Senior Vice President and Head of U.S. Commercial Operations reported to Anthony Kim that he would direct Relief's market access strategy and operations to ensure timely and effective access to Relief's products for patients in the United States.

The head of U.S. market access also signifies many important milestones for Relief. He further added that they have completed the hiring of the U.S. Commercial Team and are one step closer to providing patients access to treatments for diseases with high unmet medical needs. 

Mr, Kim also added that as we continue to grow, David's more than 20 years of extensive commercial experience working with payors, physicians, and specialty pharmacies to help ensure access for patients and their families will be invaluable.

Moreover, with the expertise and relationships forged during his tenures at Mirum Pharmaceuticals, we look forward to leveraging his broad knowledge of market access in preparation for our October 2022 U.S. continued commercialization of Relief products on the horizon. David serves as a welcome addition to our commercial leadership team.

Moreover, Relief aims to develop a robust therapeutic portfolio for rare and ultra-rare diseases that synergistically aligns with my desire to increase patient access to rare disease treatment options. Mr. McCullogh also added that I look forward to contributing to the commercial sales and additional products.

Background & Previous Professional Career:

Before joining Relief, Mr. McCullough served as National Account Director at Mirum Pharmaceuticals Inc. It is a biopharmaceutical company that focused on the treatment of rare diseases, where he was responsible for building out the company's Medicaid launch strategy and supporting the expansion of key market access policies.

He also holds several positions of increasing responsibility of holding and managing the National Accounts at Novartis Gene Therapies. Moreover, he was responsible for successfully negotiating multiple Value-Based Agreements and ten state Medicaid policies.

Before that, he worked as a Patient Access Liaison at Spark Therapeutics, supporting the launch of first-of-its-kind gene therapy in the inherited retinal disease space. He also aided in the build-out of patient services and market access operations.

Also, Mr. McCullough held numerous market access and commercial operations positions at various biotechnology and pharmaceutical companies, including an Institutional Specialty Manager at MedImmune and a Territory Manager at Abbott Laboratories.

Besides this, Mr. McCullough earned a B.A. in Speech/Public Relations from McNeese State University, a B.S. in Ministry and Theology from St. Louis Christian College, and served four years in the United States Coast Guard.

About RELIEF THERAPEUTICS Holding S.A.

Relief is a Swiss commercial-stage biopharmaceutical company focused on the identification, development, and commercialization of novel, patent-protected products. The company was found in founded in 2013. The headquarter of this company is established in Switzerland. 

The company is holding the common stock under the name of RLFTF Stock. The company is intended to perform many operations for the treatment of metabolic, dermatological, and pulmonary rare diseases with a portfolio of clinical and marketed assets that serve unmet patient needs.

The maximum price of this stock in the previous five years was 0.62 US dollars on August 7, 2020. At the same time, the minimum price of RLFTF Stock in the previous five years was 0.030 on June 10, 2022.

Financial Statements Analysis tells that the historical annual earnings are declined to 26.6% per year over the past five years. At the end of the year 2021, the earnings are -36.21 million U.S. dollars. For further information, one can connect to OTC Wiki.